Puma Biotechnology, Inc. Stock News
$8.51
3.09%
Nasdaq, Nov 09, 03:08 pm EST.
Market open.
Puma Biotechnology, Inc. Stock News
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced its third quarter earnings on Nov. 5 and followed with a conference call to provide a corporate update.
LOS ANGELES--(BUSINESS WIRE)--Puma biotechnology reported that it granted inducement awards in October 2026, as required under Nasdaq Listing Rule 5635(c)(4).
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of an inducement award to one new hire in Sept. 2026, as required under Nasdaq Listing Rule 5635(c)(4).
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call beginning at 1:30 p.m. PT on Aug. 6, following release of its earnings results for 2Q-2026.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
